These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20424538)

  • 1. Gastrointestinal involvement in patients with systemic sclerosis.
    Wielosz E; Borys O; Zychowska I; Majdan M
    Pol Arch Med Wewn; 2010 Apr; 120(4):132-6. PubMed ID: 20424538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis.
    Bae S; Allanore Y; Furst DE; Bodukam V; Coustet B; Morgaceva O; Maranian P; Khanna D
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):57-63. PubMed ID: 23910611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
    Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
    Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
    Hisada S; Takeuchi S; Tozawa T; Yamada Y; Ito Y; Kodera M
    J Dermatol; 2024 Oct; 51(10):1329-1334. PubMed ID: 38963343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
    Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
    Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis sine scleroderma and limited cutaneous systemic sclerosis: similarities and differences.
    Simeón-Aznar CP; Tolosa-Vilella C; Gabarró-Juliá L; Campillo-Grau M; Guillén Del Castillo A; Fonollosa-Plá V; Vilardell-Tarrés M
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-33-40. PubMed ID: 24776173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.
    Ntoumazios SK; Voulgari PV; Potsis K; Koutis E; Tsifetaki N; Assimakopoulos DA
    Semin Arthritis Rheum; 2006 Dec; 36(3):173-81. PubMed ID: 17045629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of organ‑specific antibodies in patients with systemic sclerosis.
    Wielosz E; Majdan M; Koszarny A; Dryglewska M; Tabarkiewicz J
    Pol Arch Med Wewn; 2016 Oct; 126(11):862-869. PubMed ID: 27906879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution oesophageal manometry and 24-hour impedance-pH study in systemic sclerosis patients: association with clinical features, symptoms and severity.
    Raja J; Ng CT; Sujau I; Chin KF; Sockalingam S
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):115-121. PubMed ID: 26843456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
    Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
    J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
    Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function.
    Kawashiri SY; Nishino A; Igawa T; Takatani A; Shimizu T; Umeda M; Fukui S; Okada A; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakashima M; Mizokami A; Matsuoka N; Migita K; Ogawa F; Ikeda S; Maemura K; Nakamura H; Origuchi T; Maeda T; Kawakami A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):102-108. PubMed ID: 29652651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esophageal and anorectal involvement in systemic sclerosis: a systematic assessment with high resolution manometry.
    Luciano L; Granel B; Bernit E; Harle JR; Baumstarck K; Grimaud JC; Bouvier M; Vitton V
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):63-69. PubMed ID: 27243115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
    Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
    Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis.
    Ingegnoli F; Galbiati V; Zeni S; Meani L; Zahalkova L; Lubatti C; Soldi A; Paresce E; Murgo A; Crapanzano C; Fantini F
    Clin Rheumatol; 2007 Apr; 26(4):510-4. PubMed ID: 16670827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal manifestations of systemic sclerosis.
    Abu-Shakra M; Guillemin F; Lee P
    Semin Arthritis Rheum; 1994 Aug; 24(1):29-39. PubMed ID: 7985035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.
    Moinzadeh P; Aberer E; Ahmadi-Simab K; Blank N; Distler JH; Fierlbeck G; Genth E; Guenther C; Hein R; Henes J; Herich L; Herrgott I; Koetter I; Kreuter A; Krieg T; Kuhr K; Lorenz HM; Meier F; Melchers I; Mensing H; Mueller-Ladner U; Pfeiffer C; Riemekasten G; Sárdy M; Schmalzing M; Sunderkoetter C; Susok L; Tarner IH; Vaith P; Worm M; Wozel G; Zeidler G; Hunzelmann N;
    Ann Rheum Dis; 2015 Apr; 74(4):730-7. PubMed ID: 24389298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colonic Manifestations and Complications Are Relatively Under-Reported in Systemic Sclerosis: A Systematic Review.
    Brandler JB; Sweetser S; Khoshbin K; Babameto M; Prokop LJ; Camilleri M
    Am J Gastroenterol; 2019 Dec; 114(12):1847-1856. PubMed ID: 31805016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
    Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
    J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.